Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson’s Disease

The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa

(2014) R. Cilia et al.   BRAIN

Rasagiline: A Review of Its Use in the Treatment of Idiopathic Parkinson’s Disease

(2014) Paul L. McCormack   CNS DRUGS

The medical treatment of Parkinson disease from James Parkinson to George Cotzias

(2014) Stanley Fahn   MOVEMENT DISORDERS

Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease

(2014) Rupam Borgohain et al.   MOVEMENT DISORDERS

Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease

(2014) Robert A. Hauser et al.   MOVEMENT DISORDERS

Prevalence of fatigue in Parkinson disease and its clinical correlates

(2014) F. Stocchi et al.   NEUROLOGY

Essential difference between the pharmacological spectrum of (−)-deprenyl and rasagiline

(2014) Ildikó Miklya   Pharmacological Reports

Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release

(2014) John P.M. Finberg   PHARMACOLOGY & THERAPEUTICS

Serotonin Toxicity Association with Concomitant Antidepressants and Rasagiline Treatment: Retrospective Study (STACCATO)

(2014) Michel Panisset et al.   PHARMACOTHERAPY

Safinamide for the treatment of Parkinson’s disease

(2014) Rukmini Mridula Kandadai et al.   Expert Review of Clinical Pharmacology

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial

(2013) Anthony HV Schapira et al.   LANCET NEUROLOGY

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations

(2013) Rupam Borgohain et al.   MOVEMENT DISORDERS

Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease

(2013) C. Warren Olanow et al.   MOVEMENT DISORDERS

Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys

(2013) Laurent Grégoire et al.   PARKINSONISM & RELATED DISORDERS

Dopamine protects neurons against glutamate-induced excitotoxicity

(2013) A Vaarmann et al.   Cell Death & Disease

Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease

(2012) A. H. V. Schapira et al.   EUROPEAN JOURNAL OF NEUROLOGY

Indirect Comparisons of Adverse Events and Dropout Rates in Early Parkinson's Disease Trials of Pramipexole, Ropinirole, and Rasagiline

(2012) Francisco J. Zagmutt et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease

(2012) I. H. Richard et al.   NEUROLOGY

l-dopa-induced dopamine synthesis and oxidative stress in serotonergic cells

(2012) Branden J. Stansley et al.   NEUROPHARMACOLOGY

Medical Management of Parkinsons Disease: Focus on Neuroprotection

(2011) Camilo Rios et al.   Current Neuropharmacology

The Monoamine Oxidase Type B Inhibitor Rasagiline in the Treatment of Parkinson Disease: Is Tyramine a Challenge?

(2011) Jack J. Chen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes

(2011) Olivier Rascol et al.   LANCET NEUROLOGY

Freezing of gait: moving forward on a mysterious clinical phenomenon

(2011) John G Nutt et al.   LANCET NEUROLOGY

Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease

(2011) Rebecca Stowe et al.   MOVEMENT DISORDERS

A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients

(2011) Fabrizio Stocchi et al.   MOVEMENT DISORDERS

Does levodopa accelerate the pathologic process in Parkinson disease brain?

(2011) L. Parkkinen et al.   NEUROLOGY

Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial

(2011) Hideyuki Sawada et al.   PLoS One

Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease

(2011) Bradley Robottom   Patient Preference and Adherence

Clinical Pharmacology Tyramine Challenge Study to Determine the Selectivity of the Monoamine Oxidase Type B (MAO-B) Inhibitor Rasagiline

(2010) Tamar Goren et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A brief history of levodopa

(2010) Oleh Hornykiewicz   JOURNAL OF NEUROLOGY

Selegiline use is associated with a slower progression in early Parkinson’s disease as evaluated by Hoehn and Yahr Stage transition times

(2010) Y.J. Zhao et al.   PARKINSONISM & RELATED DISORDERS

Medical Treatment of Parkinson Disease

(2009) Mark Stacy   NEUROLOGIC CLINICS

A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease

(2009) C. Warren Olanow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rasagiline in neurodegeneration

(2008) Anthony H.V. Schapira   EXPERIMENTAL NEUROLOGY

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

(2008) Robert A. Hauser et al.   MOVEMENT DISORDERS